Control of experimental massive periretinal proliferation by daunomycin: dose-response relation

Wiedemann, Peter; Kirmani, Muzaffar; Galvao, Manoela; Sorgente, Nino; Ryan, Stephen J.

doi:10.1007/bf02308080

Cited by 42 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that DNR seemed to be effective to suppress reproliferation, but that care should be taken to avoid postoperative complications. 9,[22][23][24][25] Some workers 10,11 have performed research into use of DNR as an agent for preventing PCO. They noted that DNR could effectively inhibit the proliferation of human lens epithelial cells in vitro at the concentration of 0.5 mg/ml, almost reaching the greatest effect at the concentration of 7.5 mg/ml.…”

Section: Daunorubicinmentioning

confidence: 99%

Evaluation of efficacy and safety of daunorubicin in glaucoma filtering surgery

Varma

Sihota

Agarwal

2006

Eye

View full text Add to dashboard Cite

Purpose To evaluate the intraocular pressure (IOP)-lowering effect and ocular side effects of daunorubicin (DNR) in drug-modulated trabeculectomy. Methods A prospective pilot study was conducted in which 21 Asian patients of Indian origin with high risk factors for failure of trabeculectomy were recruited. An approval from research ethics committee and an informed consent from every patient included in the study were obtained. DNR, an antimetabolite with known antifibroblastic action was used intraoperatively. A limbusbased conjunctival flap followed by conventional trabeculectomy was performed in all eyes. During trabeculectomy, a cellulose sponge soaked in 0.2 mg/ml DNR was applied for 3 min at the proposed site of trabeculectomy before preparation of the partial thickness scleral flap. A regular followup was carried out for 1 year where parameters including visual acuity, IOP by applanation tonometry, and slit lamp examination were performed on each visit. An IOP of 21 mmHg or less was taken as criteria for success. Results Following DNR trabeculectomy, the IOP was lowered from baseline preoperative value of 36.1975.9 to 16.0572.52 mmHg at the end of 1 year. Success rate of 81% (17 out of 21 patients) was noted. None of the patients developed corneal epithelial toxicity, hypotony maculopathy, or choroidal detachment. Conclusion The authors feel that intraoperative daunorubicin is safe and effective in lowering IOP in high-risk surgical cases of glaucoma. However, a much larger cohort study over a considerable number of years will eventually demonstrate its safety.

show abstract

Section: Daunorubicinmentioning

confidence: 99%

Evaluation of efficacy and safety of daunorubicin in glaucoma filtering surgery

Varma

Sihota

Agarwal

2006

Eye

View full text Add to dashboard Cite

show abstract

“…Various antiproliferative drugs were sug gested as possible alternatives to 5-FU ad ministered intravitreally in order to prevent P V R , such as daunomycin [8] and Taxol [9]. Among other parameters, evaluation o f the effect o f any drug to be suggested as an alter native should be compared to the effect of 5-FU or its sustained-release analogue, when the treated eyes (by 5-FU) and the control eyes were in different animals, as recom mended.…”

Section: Discussionmentioning

confidence: 99%

Further Observations on the Prevention of Experimental Proliferative Vitreo-Retinopathy by 5-Fluorouracil

Ophir¹

1991

Ophthalmic Res

View full text Add to dashboard Cite

The rate of retinal detachment in fellow control eyes of rabbits following fibroblast administration is progressively lower with increased dose of 5-Fluorouracil in the test eyes. Thus, it seems mandatory to choose control eyes in other animals rather than the fellow eyes of the treated ones. Retinal detachment appeared in the second week or earlier after intravitreal fibroblast administration. However, in eyes treated intravitreally with 5-Fluorouracil, retinal detachment or pucker appeared later, even in the second month suggesting routine follow-up of at least 2 months in future studies.

show abstract

“…22 Previous studies have shown that the anthracycline drug DNR is effective in inhibiting PVR formation. 23,24 Unfortunately, DNR has a short half-life in the eye vitreous coupled with a narrow therapeutic concentration range, thus requiring frequent injections over time. 25 Therefore, a sustained delivery system is needed to control the drug release within its therapeutic window.…”

Section: Introductionmentioning

confidence: 99%